Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24758290 | 1.00 | NR3C1 (0.38) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24757816 | 0.95 | NR3C1 (0.40) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL30106989 | 0.95 | NR3C1 (0.40) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL30107029 | 0.89 | BACE1 (0.38) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24757308 | 0.89 | BACE1 (0.38) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24906533 | 0.86 | SCN10A (0.43) | NR3C1AKR1C3AKR1C2 | |
| SCHEMBL30107007 | 0.85 | AKR1C3 (0.39) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24758208 | 0.85 | AKR1C3 (0.39) | NR3C1AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24759014 | 0.85 | NR3C1 (0.40) | NR3C1AKR1C3AKR1C2BACE1CRHR1 | |
| SCHEMBL30107047 | 0.85 | NR3C1 (0.40) | NR3C1AKR1C3AKR1C2BACE1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | NR3C1 2106/4885AKR1C3 1950/4885AKR1C2 1995/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | NR3C1 2106/4885AKR1C3 1950/4885AKR1C2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.